Skip to main content

Table 2 Univariate Cox proportional hazards model predicting androgen deprivation therapy-free survival and progression-free survival

From: Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Covariate ADT-FS   PFS  
  HR (95% CI) p-value HR (95% CI) p-value
Prognostic group at diagnosis     
 Low-Intermediate 1 0.72 1 0.41
 High 0.99 (0.36 – 2.74)   0.78 (0.33 – 1.88) 0.58
 Very high 1.45 (0.48 – 4.4)   1.40 (0.56 – 3.53) 0.47
Interval from diagnosis to metastases (yr) 1 (0.99 – 1.01) 0.51 1 (0.99 – 1.01) 0.55
PSA level at time of metastases (ng/ml) 1 (0.97 – 1.03) 0.96 1 (0.98 – 1.03) 0.67
PSA DT at time of metastases (mo) 0.83 (0.71 – 0.97) 0.02 0.90 (0.82 – 0.99) 0.04
Number of lesions at diagnosis of metastases 1.11 (0.56 – 2.22) 0.75 1.02 (0.53 – 1.94) 0.96
Pattern of metastatic spread     
 Minimal 1 0.37 1 0.27
 Extensive 1.48 (0.63 – 3.49)   1.53 (0.72 – 3.2)  
Location of metastasis*     
 Node 1 0.10 1 0.25
 Bone 2.02 (0.87 – 4.72)   1.54 (0.74 – 3.22)  
  1. Abbreviation: HR hazard ratio, CI confidence interval, yr year, mo month, ADT-FS androgen deprivation therapy-free survival, PFS progression-free survival.
  2. *The patient with liver metastasis was excluded from the analysis of this variable. P-values in bold represent significant values <0.05.